Fig. 2.

BID is required for tumor suppression by NSAIDs in APC^Min/+ mice. Age- and sex-matched APC^Min/+ mice with different BID genotypes were fed control or NSAID-containing AIN93G diet. (A) Representative images of small intestine and colon from BID^+/+ and BID^−/− APC^Min/+ mice treated with sulindac (200 ppm) for 4 mo, with arrows indicating visible macroadenomas. (B) Representative images of small intestine and colon of control mice and mice treated with sulindac (200 ppm) for 2 mo, with arrows indicating microscopic lesions. (C) Mean numbers + SD of small intestinal and colonic adenomas (≥0.5 mm in diameter) in BID^+/+, BID^+/−, and BID^−/− APC^Min/+ mice treated ± sulindac as in B. *P < 0.05; **P < 0.01; ***P < 0.001 (n = 4 per group). (D) Kaplan–Meier survival curves of BID^+/+ and BID^−/− APC^Min/+ mice treated ± sulindac (200 ppm) for 70 wk. BID^+/+ vs. BID^−/− APC^Min/+ mice, P = 0.0005 (log-rank test). (Scale bars: A, 1 cm; B, 2 mm.)